<DOC>
	<DOCNO>NCT00002550</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . It yet know chemotherapy plus radiation therapy effective without surgery lung cancer . PURPOSE : Randomized phase III trial compare effectiveness combine cisplatin , etoposide , radiation therapy without surgery treating patient stage IIIA non-small cell lung cancer .</brief_summary>
	<brief_title>Chemotherapy Plus Radiation Therapy With Without Surgery Treating Patients With Stage IIIA Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free survival , median ( 2-year ) survival , long-term ( 5-year ) survival patient newly diagnose , stage IIIA ( N2 ) non-small cell lung cancer treat radiotherapy concurrently cisplatin etoposide without surgical resection . Secondary - Compare pattern local distant failure patient treat regimen . - Determine relationship tobacco use , alcohol use , diet toxicity regimens outcome men woman . OUTLINE : This randomize , multicenter study . Patients stratify contralateral mediastinal sampling biopsy ( yes v ) , tumor stage ( T1 vs T2 v T3 ) , performance status ( 70-80 % vs 90-100 % ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive induction cisplatin IV 1 hour day 1 8 etoposide IV 1 hour day 1-5 . Treatment continue every 4 week 2 course absence disease progression unacceptable toxicity . Beginning within 24 hour first dose chemotherapy , patient undergo induction radiotherapy 5 day week 5 week absence disease progression unacceptable toxicity . Patients without local progression distant metastases 2-4 week completion course 2 undergo resection approximately 3-5 week completion course 2 . All visible , accessible bronchopulmonary , hilar , mediastinal lymph node excise . The choice surgical procedure ( thoracotomy , lobectomy , pneumonectomy en bloc resection tumor extend parietal pleura , chest wall , pericardium , diaphragm ) discretion surgeon . Patients undergo resection receive 2 additional course chemotherapy alone begin 4-6 week postoperatively . Patients unresectable disease medically unfit refuse resection receive 2 additional course chemotherapy alone begin immediately completion course 2 . - Arm II : Patients undergo induction chemoradiotherapy arm I undergo resection . Patients without local progression distant metastasis within 1 week anticipate completion induction radiotherapy receive 2 additional course chemotherapy begin immediately completion course 2 . Patients without local distant progression completion course 4 undergo boost radiotherapy 8 day . Patients follow every 2 month 1 year , every 3 month 2 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 510 patient accrue study within 4.9 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven newly diagnose , stage IIIA ( T13 , N2 ) nonsmall cell lung cancer Eligible subtypes : Adenocarcinoma Large cell carcinoma Squamous cell carcinoma Nonlobar nondiffuse bronchoalveolar cell carcinoma Measurable evaluable disease chest xray and/or contrast CT scan Contrast thoracic CT require complete stag Single primary bronchogenic tumor ( 1 parenchymal lung lesion ) Pleural effusion allow 1 follow condition meet : Negative cytology thoracentesis effusion present mediastinoscopy exploratory thoracotomy Effusion see CT scan chest xray deem small tap CT ultrasound guidance Positive ipsilateral mediastinal node ( ) without positive ipsilateral hilar node Mediastinal node separate primary lesion CT scan surgical exploration Histologic cytologic proof N2 disease thoracotomy , mediastinoscopy , mediastinotomy , Chamberlain procedure , Wang needle , fine needle aspiration bronchoscopic CT guidance Nodal biopsy aspiration waive following condition meet : Paralyzed leave true vocal cord document bronchoscopy indirect laryngoscopy Nodes visible Level 5 region CT scan Distinct primary lesion separate node CT scan All mediastinal nodal involvement map ( positive negative ) No positive node contralateral mediastinum ( supraclavicular area higher ) neck Mediastinoscopy , mediastinotomy , Chamberlain procedure , thoracotomy require node large 1 cm contrast CT scan Surgery waive node negative large 1 cm CT scan Lymphadenopathy allow biopsy proof benign cause No metastases contrast CT MRI scan brain , bone scan , CT scan lung exclude ipsilateral contralateral parenchymal lesion , contrast CT scan upper abdomen include entire liver adrenals No hepatomegaly splenomegaly physical examination CT scan unless documentation benign cause No pericardial effusion No superior vena cava syndrome No prior diagnosis lung cancer PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 90100 % ( 7080 % allow albumin least 0.85 time low limit normal weight loss great 10 % within 3 month diagnosis ) Hematopoietic : White blood cell count ( WBC ) least 4,000/mm^3 OR Granulocyte count least 2,000/mm^3 Platelet count normal Hemoglobin least 10.0 g/dL ( le 8.5 g/dL allow marrow involvement tumor ) Hepatic : See Performance status Bilirubin great 1.5 time upper limit normal ( ULN ) * Serum glutamate oxaloacetate transaminase ( SGOT ) serum glutamate pyruvate transaminase ( SGPT ) great 1.5 time ULN* NOTE : * Unless documentation benign cause Renal : Creatinine clearance least 50 mL/min Cardiovascular : No myocardial infarction within past 3 month No active angina No unstable arrhythmia No congestive heart failure Pulmonary : Forced expiratory volume one second ( FEV1 ) least 2.0 liter OR Predicted postresection FEV1 least 800 mL base quantitative V/Q scan Diffusion capacity lung carbon monoxide ( DLCO ) least 50 % predict ( correct hemoglobin ) pneumonectomy plan likely induction chemotherapy Other : No clinically significant hearing loss unless willing accept potential loss No symptomatic peripheral neuropathy No peptic ulcer disease active treatment No medical illness controllable appropriate medical therapy No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , ductal lobular carcinoma situ breast Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent colonystimulating factor Chemotherapy : No prior chemotherapy lung cancer No concurrent chemotherapy another condition ( arthritis ) Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy lung cancer Surgery : See Disease Characteristics No prior resection primary tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>